NCT03157128 2026-04-16LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 24 charts 3 FDA
NCT04268550 2026-03-23Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)SWOG Cancer Research NetworkPhase 2 Active not recruiting124 enrolled